Not Medicare Enrolled

Dr. Alvaro Dangond, M.D.

Pediatrics · Miami, FL
Low-engagement
7001 SW 97TH AVE STE 201, Miami, FL 33173
3055954478
In practice since 2005 (20 years)
NPI: 1316932247 verify on NPPES ↗
Moderate
DATA COVERAGE
Data in 2 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Dangond from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Dangond? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Dangond

Dr. Alvaro Dangond is a pediatrics in Miami, FL, with 20 years in practice.

Between the years covered by Open Payments, Dr. Dangond received a total of $4,599 from 35 pharmaceutical and/or device companies across 244 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pediatrics. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Dangond is Moderate — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice$ $4,599 industry payments

Industry Payment Transparency

Open Payments through 2024 ↗
$4,599
Total received (2018-2024)
Avg $657/year across 7 years
Top 3% in FL for pediatrics
35
Companies
244
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,599 (100.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,154
2023
$714
2022
$480
2021
$824
2020
$401
2019
$326
2018
$700

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$732
Supernus Pharmaceuticals, Inc.
$714
GlaxoSmithKline, LLC.
$307
Corium, LLC
$271
Tris Pharma Inc
$242
Takeda Pharmaceuticals U.S.A., Inc.
$231
SANOFI-AVENTIS U.S. LLC
$217
Cranial Technologies, Inc
$191
ALK-Abello, Inc
$191
AstraZeneca Pharmaceuticals LP
$185
SANOFI PASTEUR INC.
$156
Shire North American Group Inc
$111
Ironshore Pharmaceuticals Inc.
$99
Adlon Therapeutics L.P.
$97
Seqirus USA Inc
$89
Merck Sharp & Dohme LLC
$85
Genentech USA, Inc.
$84
kaleo, Inc.
$82
Merck Sharp & Dohme Corporation
$80
Phadia US Inc.
$53
IRONSHORE PHARMACEUTICALS INC.
$44
Galderma Laboratories, L.P.
$41
Sanofi Pasteur Inc.
$38
Sarepta Therapeutics, Inc.
$35
Mission Pharmacal Company
$31
Vanda Pharmaceuticals Inc.
$27
Verrica Pharmaceuticals Inc.
$24
Kowa Pharmaceuticals America, Inc.
$24
Corium, Inc.
$20
Ultragenyx Pharmaceutical Inc.
$19
AbbVie Inc.
$19
Neos Therapeutics, LP
$18
Mylan Pharmaceuticals Inc.
$15
Kaleo, Inc.
$15
AIMMUNE THERAPEUTICS, INC.
$13
Top 3 companies account for 38.1% of total payments
Associated products mentioned in payments ›
ADACEL · ADHANSIA XR · AKLIEF · AUVI-Q · AZSTARYS · Adzenys XR-ODT · Auvi-Q · Azstarys · BEXSERO · BOOSTRIX · Clindamycin Phosphate and Benzoyl Peroxide · Doc Band · Dyanavel XR · EUCRISA · EXONDYS 51 · FLUCELVAX QUADRIVALENT · FLUMIST QUADRIVALENT · Flucelvax · GARDASIL · GARDASIL 9 · HETLIOZ · ImmunoCAP · JORNAY PM · Jornay PM 20mg capsules (Bottle of 100) · LUPRON DEPOT · M-M-R II · MENACTRA · MENQUADFI · MYDAYIS · Odactra · PAXLOVID · PENTACEL · PREVNAR - 13 · PREVNAR 13 · PREVNAR 20 · Prednisolone 25 · QELBREE · QUADRACEL · QUILLICHEW ER · Qelbree · Quillivant · Quillivant XR · ROTATEQ · SYNAGIS · TRINTELLIX · TRUMENBA · TZIELD · VAXELIS · VYVANSE · Xofluza · YCANTH · ZORYVE
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 3% for pediatrics in FL.

Looking for a pediatrics in Miami?
Compare pediatricss in the Miami area by procedure volume, costs, and industry payment transparency.
Browse pediatricss nearby

Geographic Context

Pediatricss within 10 mi
857
Per 100K population
31.9
County median income
$68,694
Nearest hospital
BAPTIST HOSPITAL OF MIAMI
3.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment— Not enrolledN/A
Practice Data— No dataN/A
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 2 of 4 available federal datasets, with a Data Coverage level of Moderate. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Dangond is a pediatrics, and high industry engagement (low-engagement, top 3%), with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Dangond receive payments from pharmaceutical companies?
Yes. Dr. Dangond received a total of $4,599 from 35 companies across 244 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently Moderate for Dr. Dangond) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →